Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: A large cross-sectional study

RMD Open

Volumn 5, Issue 1, 2019, Pages

  Smolen, Josef S ^a   Gladman, Dafna ^b   McNeil, H Patrick ^c   Mease, Philip J ^d   Sieper, Joachim ^e   Hojnik, Maja ^f   Nurwakagari, Pascal ^f   Weinman, John ^g  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c MACQUARIE UNIVERSITY   (Australia)

^d UNIVERSITY OF WASHINGTON   (United States)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f ABBVIE INC   (United States)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

adherence; ankylosing spondylitis; disease modifying antirheumatic drugs; psoriatic arthritis; rheumatoid arthritis

Indexed keywords

AZATHIOPRINE; CYCLOSPORINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGING; ANKYLOSING SPONDYLITIS; ARTICLE; CAUCASIAN; COMBINATION DRUG THERAPY; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE DURATION; ETHNICITY; FEMALE; HEALTH BELIEF; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MONOTHERAPY; MORISKY MEDICATION ADHERENCE SCALE; MORISKY-GREEN-LEVINE TEST; MULTICENTER STUDY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PSORIATIC ARTHRITIS; RACE DIFFERENCE; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SYSTEMIC THERAPY; TREATMENT RESPONSE;

EID: 85059902175     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2017-000585     Document Type: Article

References (41)

1. Contreras-Yanez I, Ponce De Leon S, Cabiedes J, et al. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with diseasemodifying antirheumatic drugs. Am J Med Sci 2010;340:282-90.
2. Bluett J, Morgan C, Thurston L, et al. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology 2015;54:494-9.
3. Waimann CA, Marengo MF, de Achaval S, et al. Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence. Arthritis Rheum 2013;65:1421-9.
4. De Vera MA, Mailman J, Galo JS. Economics of non-adherence to biologic therapies in rheumatoid arthritis. Curr Rheumatol Rep 2014;16:460.
5. Tang B, Rahman M, Waters HC, et al. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 2008;30:1375-84.
6. Vangeli E, Bakhshi S, Baker A, et al. A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther 2015;32:983-1028.
7. Horne R, Chapman SC, Parham R, et al. Understanding patients' adherence-related beliefs about medicines prescribed for longterm conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS One 2013;8:e80633.
8. Betegnie AL, Gauchet A, Lehmann A, et al. Why do patients with chronic inflammatory rheumatic diseases discontinue their biologics? An assessment of patients' adherence using a self-report questionnaire. J Rheumatol 2016;43:724-30.
9. Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor á inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 2013;72:1149-55.
10. Iannone F, Lopriore S, Bucci R, et al. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA. Scand J Rheumatol 2015;44:192-9.
11. Lie E, van der Heijde D, Uhlig T, et al. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis 2010;69:671-6.
12. Pavelka K, Forejtova S, Stolfa J, et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol 2009;27:958-63.
13. Kristensen LE, Karlsson JA, Englund M, et al. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res 2010;62:1362-9.
14. Glintborg B, Ostergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor á therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011;63:382-90.
15. Saad AA, Ashcroft DM, Watson KD, et al. Persistence with antitumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 2009;11:R52.
16. Michetti P, Weinman J, Mrowietz U, et al. Impact of treatmentrelated beliefs on medication adherence in immune-mediated inflammatory diseases: results of the global ALIGN study. Adv Ther 2017;34:91-108.
17. Broadbent E, Petrie KJ, Main J, et al. The Brief Illness Perception Questionnaire. J Psychosom Res 2006;60:631-7.
18. Broadbent E, Wilkes C, Koschwanez H, et al. A systematic review and meta-analysis of the Brief Illness Perception Questionnaire. Psychol Health 2015;30:1361-85.
19. Horne R, Weinman J, Hankins M. The Beliefs about Medicines Questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14:1-24.
20. Morisky DE, DiMatteo MR. Improving the measurement of selfreported medication nonadherence: response to authors. J Clin Epidemiol 2011;64:255-7.
21. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67-74.
22. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.
23. van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti- TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905-8.
24. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 2016;68:282-98.
25. Aikens JE, Nease DE, Nau DP, et al. Adherence to maintenancephase antidepressant medication as a function of patient beliefs about medication. Ann Fam Med 2005;3:23-30.
26. Rice ME, Harris GT. Comparing effect sizes in follow-up studies: ROC Area, Cohen's d, and r. Law Hum Behav 2005;29:615-20.
27. Brain C, Allerby K, Sameby B, et al. Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMSR) in the Swedish COAST-study. Eur Neuropsychopharmacol 2013;23:1754-62.
28. Bourdes V, Ferrieres J, Amar J, et al. Prediction of persistence of combined evidence-based cardiovascular medications in patients with acute coronary syndrome after hospital discharge using neural networks. Med Biol Eng Comput 2011;49:947-55.
29. Chang DS, Friedman DS, Frazier T, et al. Development and validation of a predictive model for nonadherence with once-daily glaucoma medications. Ophthalmology 2013;120:1396-402.
30. Connelly J, Pilch N, Oliver M, et al. Prediction of medication nonadherence and associated outcomes in pediatric kidney transplant recipients. Pediatr Transplant 2015;19:555-62.
31. Drachler ML, Drachler CW, Teixeira LB, et al. The scale of selfefficacy expectations of adherence to antiretroviral treatment: a tool for identifying risk for non-adherence to treatment for HIV. PLoS One 2016;11:e0147443.
32. Kawakami A, Tanaka M, Nishigaki M, et al. A screening instrument to identify ulcerative colitis patients with the high possibility of current non-adherence to aminosalicylate medication based on the Health Belief Model: a cross-sectional study. BMC Gastroenterol 2014;14:220.
33. Neame R, Hammond A. Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. Rheumatology 2005;44:762-7.
34. Pasma A, van't Spijker A, Hazes JM, et al. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Semin Arthritis Rheum 2013;43:18-28.
35. Treharne GJ, Lyons AC, Kitas GD. Medication adherence in rheumatoid arthritis: effects of psychosocial factors. Psychol Health Med 2004;9:337-49.
36. van den Bemt BJ, van den Hoogen FH, Benraad B, et al. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol 2009;36:2164-70.
37. Zwikker HE, van Dulmen S, den Broeder AA, et al. Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis. Patient Prefer Adherence 2014;8:1635-45.
38. Mena-Vazquez N, Manrique-Arija S, Yunquera-Romero L, et al. Adherence of rheumatoid arthritis patients to biologic diseasemodifying antirheumatic drugs: a cross-sectional study. Rheumatol Int 2017;37:1709-18.
39. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1-26.
40. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
41. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499-510.